MRK/MRNA's personalized cancer therapy delivers first phase III win
- Posted on August 20, 2026
- By Bing News
- 1 Views
- 1 min read
In brief
Generating AI summary…
MRK/MRNA's personalized cancer therapy delivers first phase III win
Shares of both Merck MRK and its partner Moderna MRNA jumped to a 52-week high yesterday after the companies announced positive top-line data from a phase III study, which evaluated their personalized cancer therapy combo in certain patients with high-risk melanoma, a serious form of skin cancer. The phase III INTerpath-001 study evaluated Moderna’s investigational mRNA-based individualized neoantigen therapy (“INT”), intismeran autogene...
